Posted by Michael Wonder on 17 Dec 2015

FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes

FDA

16 December 2015 - The U.S. FDA today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Biosimilar